Related Experiment Video
Updated: Feb 21, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
PSA screening for prostate cancer
1Adjunct Professor, Habilitation degree (Livre-docência) in Urology, Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM-Unifesp). Head of the Urologic Oncology Sector at EPM-Unifesp. Graduate degrees from Harvard Medical School and The Johns Hopkins School of Medicine. Member of Academia de Medicina de São Paulo, São Paulo, SP, Brazil.
Prostate cancer screening using prostate-specific antigen (PSA) is controversial. This review analyzes PSA testing recommendations, proposing selective use based on baseline values for better prostate cancer early diagnosis.
Area of Science:
- Urology
- Oncology
- Preventive Medicine
Background:
- Prostate-specific antigen (PSA) screening for prostate cancer remains controversial.
- Confusion exists between population screening and early diagnosis.
- Concerns include study quality, treatment outcomes for low-grade tumors, and treatment-related quality of life issues.
Purpose of the Study:
- To critically analyze current PSA testing recommendations.
- To incorporate new data from re-evaluated studies and updated USPSTF guidelines.
- To propose a more rational and selective approach to PSA screening.
Main Methods:
- Review of existing prostate cancer screening studies.
- Analysis of updated USPSTF recommendation statements.
- Evaluation of new data from ongoing prostate cancer research.
Main Results:
- Current PSA screening recommendations are debated.
- Re-evaluation of studies and updated guidelines provide new insights.
- A selective PSA testing strategy is suggested.
Conclusions:
- A more rational and selective use of PSA testing is proposed.
- Baseline PSA values from age 40-50 could inform screening decisions.
- Improved prostate cancer early diagnosis and management are potential benefits.
